340B Program Lacks Price Transparency, Federal Watchdogs Tell HELP Committee
Gauging the 340B drug discount program’s effectiveness requires more price transparency and clearer guidance, expert witnesses told the Senate health committee Tuesday.
Source: Drug Industry Daily